Big Buttons

• End Drug Shortages Act intro’d in Congress

  The legislation would expand the sources the FDA may use to declare drug shortages. read more →

• FDA tirzepatide ‘reconsideration’ period extended

  FDA agreed to extend until December 19 a final report on tirzepatide availability to the court.  read more →

• NPR hits the GLP-1 nail on the head

  A National Public Radio piece this week tackled the issue of compounded GLP-1 drugs and got the facts and nuance just right. read more →

• CALL TO ACTION: Tell FDA to deny drugmakers’ request

  Drugmakers are urging FDA to prohibit compounded GLP-1s. FDA needs to hear from you and your patients NOW! read more →

• APC to FDA: Just say no to Lilly

  This week APC's lawyers sent a formal comment to the FDA about Eli Lilly’s request that tirzepatide be added to the Demonstrably Difficult to Compound list. read more →

• California BOP sends proposed compounding regs to comment period

  The California State Board of Pharmacy decided to move the modified proposed sterile compounding regulations forward to a 30-day comment period. read more →

• Checking in on the post-Chevron fallout

  What’s happened in the world of federal regulation since the end of Chevron? read more →

• Hi, Noom!

  Welcome to our newest Bronze-level Corporate Patron, Noom! read more →

More News

APC member Masoud Rashidi, vice chair of our State Legislative & Regulatory Committee, did a great job defending compounding in the Sacramento, Calif., ABC affiliate’s story “Poison control is paying attention to compounded semaglutide” which strongly implies that compounded versions are responsible for calls to poison control centers.

Masoud explained the importance of using a state-licensed pharmacy: “Stay away from the online stuff that you don’t really know where it’s coming from. If it doesn’t have a pharmacy name or doctor’s name, it’s a red flag already. It’s just not about price, sometimes it’s your life and your safety.”